Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
1.420
+0.100 (7.58%)
At close: Feb 6, 2026, 4:00 PM EST
1.408
-0.012 (-0.82%)
After-hours: Feb 6, 2026, 7:59 PM EST
Autolus Therapeutics Employees
As of December 31, 2024, Autolus Therapeutics had 650 total employees, including 647 full-time and 3 part-time employees. The number of employees increased by 179 or 38.00% compared to the previous year.
Employees
650
Change (1Y)
179
Growth (1Y)
38.00%
Revenue / Employee
$78,658
Profits / Employee
-$345,849
Market Cap
377.92M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 650 | 179 | 38.00% | 647 | 3 |
| Dec 31, 2023 | 471 | 67 | 16.58% | 463 | 8 |
| Dec 31, 2022 | 404 | 77 | 23.55% | 399 | 5 |
| Dec 31, 2021 | 327 | -57 | -14.84% | 324 | 3 |
| Dec 31, 2020 | 384 | 92 | 31.51% | 376 | 8 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 305 |
| Allogene Therapeutics | 229 |
| Entrada Therapeutics | 183 |
| Puma Biotechnology | 172 |
| Adlai Nortye | 123 |
| Aura Biosciences | 109 |
| Neumora Therapeutics | 95 |
| Aclaris Therapeutics | 64 |
AUTL News
- 3 days ago - Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 - GlobeNewsWire
- 4 weeks ago - Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform - Business Wire
- 4 weeks ago - Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform - GlobeNewsWire
- 2 months ago - Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 - GlobeNewsWire
- 2 months ago - Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025 - GlobeNewsWire
- 2 months ago - Autolus Therapeutics Appoints Ryan Richardson to Board of Directors - GlobeNewsWire
- 2 months ago - Why Is Autolus Therapeutics Stock Trading Higher On Tuesday? - Benzinga